Multidrug resistance in Mycobacterium tuberculosis

International Journal of Antimicrobial Agents

Volumn 8, Issue 1, 1997, Pages 61-70

  Heym, Beate ^a   Cole, Stewart T ^b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

ethambutol; fluoroquinolones; isoniazid; pyrazinamide; rifampicin; short course chemotherapy; streptomycin; tuberculosis

Indexed keywords

CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

CHROMOSOME; DRUG ACTIVATION; DRUG BINDING; DRUG MECHANISM; DRUG TRANSPORT; GENE MUTATION; HUMAN; MEMBRANE PERMEABILITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

EID: 0030994680     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(96)00356-1     Document Type: Article

References (123)

1. Dudley M. Bacterial resistance mechanisms to β-lactam antibiotics: assessment of management strategies. Pharmacotherapy 1995:S9-S14.
2. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995;33:24-27.
3. Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:1208-1213.
4. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-1072.
5. Sepkowitz KA, Raffalli J, Riley L, Kiehn TE, Armstrong D. Tuberculosis in the AIDS Era. Clin Microbiol Rev 1995;8:180-199.
6. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-526.
7. Iseman MD. Evolution of drug-resistant tuberculosis: a tale of two species. Proc Natl Acad Sci USA 1994;91:2428-2429.
8. Weltman AC, Rose DN. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York hospital. Arch Intern Med 1994;154:2161-2167.
9. Horsburgh Jr. CR. Epidemiology of mycobacterial diseases in AIDS. Res Microbiol 1992;143:372-377.
10. McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States 1986-1993. N Engl J Med 1995;332:1071-1076.
11. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis. J Am Med Assoc 1995;273:220-226.
12. Nikaido H, Jarlier V. Permeability of mycobacterial cell wall. Res Microbiol 1991;142:437-443.
13. Meyer H, Mally J. Über Hydrazinderivate der Pyridincarbonsäuren. Monatshefte für Chemie 1912;33:393-414.
14. Fox HH. Synthetic Tuberculostatics show promise. Chem Eng News 1951;29:3963-3964.
15. Bernstein J, Lott WA, Steinberg BA, Yale HL. Chemotherapy of experimental tuberculosis. Am Rev Tuberc 1952;65:357-364.
16. Steenken Jr. W, Wolinsky E. Antituberculous properties of hydrazines of isonicotinic acid (Rimifon, Marsalid). Am Rev Tuberc 1952;65:365-375.
17. Tsukamura M, Tsukamura S. Isotopic studies on the effect of isoniazid on protein synthesis of mycobacteria. Jpn J Tuberc 1963;11:14-17.
18. Youatt J. A review of the action of isoniazid. Am Rev Respir Dis 1969;99:729-749.
19. Barclay WR, Ebert RH, Koch-Weser D. Mode of action of isoniazid. Part I. Am Rev Tuberc 1953;67:490-496.
20. Barclay WR, Koch-Weser D, Ebert RH. Mode of action of isoniazid. Part II. Am Rev Tuberc 1954;70:784-792.
21. Middlebrook G. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am Rev Tuberc 1952;65:765-767.
22. Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953;118:297-299.
23. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-3.
24. Heym B, Zhang Y, Poulet S, Young D, Cole ST. Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J Bacteriol 1993;175:4255-4259.
25. Zhang Y. Genetic basis of isoniazid resistance of Mycobacterium tuberculosis. Res Microbiol 1993;144:143-149.
26. Loewen PC, Switala J, Triggs-Raine BL. Catalases HPI and HPII in Escherichia coli are induced independently. Arch Biochem Biophys 1985;243:144-149.
27. Triggs-Raine BL, Doble BW, Mulvey MR, Sorby PA, Loewen PC. Nucleotide Sequence of katG, encoding catalase HPI of Escherichia coli. J Bacteriol 1988;1970:4415-4419.
28. Claiborne A, Fridovich I. Purification of the o-Dianisidine Peroxidase from Escherichia coli B. J Biol Chem 1979;254:4245-4252.
29. Zhang Y. Genetic basis of isoniazid resistance of Mycobacterium tuberculosis. Res Microbiol 1993;144:143-9.
30. Johnsson K, Schultz PG. Mechanistic studies of the oxidation of isoniazid by the catalase-peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 1994;116:7425-7426.
31. Johnsson K, King D, Schultz PG. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J Am Chem Soc 1995;117:5009-5010.
32. Heym B, Alzari P, Honoré N, Cole S. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995;15:235-245.
33. Rouse DA, Li Z, Bai G-H, Morris SL. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:2472-2477.
34. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JDA. Characterization of the catalase-peroxidase gene katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996;173:196-202.
35. Welinder KG. Bacterial catalase-peroxidases are gene duplicated members of the plant peroxidase superfamily. Biochem Biophys Acta 1991;1080:215-220.
36. Morris SL, Nair J, Rouse DA. The catalase-peroxidase of Mycobacterium intracellulare: nucleotide sequence analysis and expression in Escherichia coli. J Gen Microbiol 1992;138:2363-2370.
37. Wayne LG, Diaz GA, Doubek JR. Acquired isoniazid resistance and catalase activity. Am Rev Respir Dis 1968;97:909-913.
38. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-230.
39. Rist N. L' Activité antituberculeuse de l' Ethionamide. Adv Tuberc Res 1960;10:69-126.
40. Dessen A, Quémard A, Blunchard JS, Jacobs Jr. WR, Sacchettini JC. Crystal stucture and function of the isoniazid target of Mycobacterium tuberculosis. Science 19995;267:1638-1641.
41. Kapur V, Li L-L, Hamrick MR, Plikaytis BB, Shinnick TM, Telenti A, et al. Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 1995;119:131-8.
42. Ristow M, Möhlig M, Rifai M, Schatz H, Feldmann K, Pfeiffer A. New isoniazid ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains. Lancet 1995;346:502-503.
43. Youatt J, Tham SH. An Enzyme System of Mycobacterium tuberculosis that reacts specifically with Isoniazid. II. Am Rev Respir Dis 1969;100:31-37.
44. Poole LB, Ellis HR. Flavin-dependent alkyl hydroperoxide reductase from Salmonella typhimurium. 1. Purification and Enzymatic activities of overexpressed AhpF and AhpC Proteins. Biochemistry 1996;35:56-64.
45. Tartaglia LA, Storz G, Ames BN. Identification and molecular analysis of OxyR-regulates promoters important for the bacterial adaptation to oxidative stress. J Mol Biol 1989;210:709-719.
46. Deretic V, Philipp W, Dhandayutapani S, Mudd MH, Curcic R, Garbe T, et al. Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene:implications for sensitivity to isoniazid. Mol Microbiol 1995;17:889-900.
47. Sherman DR, Sabo PJ, Hickey MJ, Arain TM, Mahairas GG, Barry CEI, et al. Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria. Proc Natl Acad Sci USA 1995;92:6625-6629.
48. Dhandayuthapani S, Zhang Y, Mudd MH, Deretic V. Oxidative stress reponse and its role in sensitivity to isoniazid in Mycobacteria: characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis. J Bacteriol 1996;187:3641-3649.
49. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry III CE, et al. Compensatory ahpC Gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996;272:1643-1643.
50. Wilson TM, Collins DM. ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 1996;19:1025-1034.
51. Grosset JH. Present status of chemotherapy for tuberculosis. Rev Infect Dis 1989;11:5347-5352.
52. Gale, EF, Cundliffe E, Reynolds PE, Richmond MH, Waring MJ. The Molecular Basis of Antibiotic Action. Wiley, London, 1981.
53. Ovchinnikov YA, Monastyrskaya GS, Guriev SO, Kalinina NF, Sverdlof ED, Gragerov AI, et al. RNA polymerase rifampicin resistance mutations in Escherichia coli: sequence changes and dominance. Mol Gen Genet 1983;190:344-348.
54. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis 1983;5:S407-S411.
55. Honoré N, Cole ST. The molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother 1993;37:414-418.
56. Miller LP, Crawford JT, Shinnick TM. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:805-811.
57. Imboden P, Cole S, Bodmer T, Telenti A. Detection of rifampin resistance mutations in Mycobacterium tuberculosis and M. leprae. In: Persing DH, Smith TF, Tenover FC, White TJ (eds) Diagnostic Molecular Microbiology. Principles and Applications. American Society for Microbiology, Washington D.C., 1993;519-526.
58. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole ST, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-650.
59. Jin DJ, Gross CA. Characterization of the pleiotropic phenotypes of rifampin-resistant rpoB mutants of Escherichia coli. J Bacteriol 1989;171:5229-5231.
60. Beenhouwer De H, Lhiang Z, Jannes G, Mijs W, Machtelinckx L, Rossau R, et al. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuberc Lung Dis 1995;76:425-30.
61. Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T. Direct, automated detection of rifampicin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother 1993;37:2054-2058.
62. Wallace BJ, Davis BD. Cyclic Blockade of initiation sites by streptomycin-damaged ribosomes in Escherichia coli:an explanation for dominance of sensitivity. J Mol Biol 1973;75:377-390.
63. Funatsu G, Wittmann HG. Location of amino acid replacements in protein S12 isolated from Escherichia coli mutants resistant to streptomycin. J Mol Biol 1975;68:547-550.
64. Weisblum B, Davies J. Antibiotic inhibitors of the bacterial ribosome. Bacteriol Rev 1968;32:493-528.
65. Garvin RT, Biswas DK, Gorini L. The Effects of streptomycin or dihydrostrepotmycin binding to 16S RNA or to 30S ribosomal subunits. Proc Nat Acad Sci USA 1974;71:3814-3818.
66. Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987;327:389-394.
67. Mitchison DA. Problems of drug resistance. Br Med Bull 1954;10:115-124.
68. Canetti G, Rist N, Grosset J. Primary drug resistance in tuberculosis. Am Rev Respir Dis 1964;90:792-799.
69. Meier A, Kirschner P, Bange F-C, Vogel U, Böttger EC. Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents Chemother 1994;38:228-233.
70. Cooksey RC, Morlock GP, McQueen A, Glickman SE, Crawford JT. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City. Antimicrob Agents Chemother 1996;40:1186-1188.
71. Kempsell KE, Ji Y-E, Estrada ICE, Colston MJ, Cox RA. The nucleotide sequence of the promoter, 16S rRNA and spacer region of the ribosomal RNA operon of Mycobacterium tuberculosis and comparison with Mycobacterium leprae precursor rRNA. J Gen Microbiol 1992;138:1717-1727.
72. Böttger E. Resistance to drugs targeting protein synthesis in mycobacteria. Trends Microbiol 1994;2:416-421.
73. Honoré N, Cole ST. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994;38:238-242.
74. Finken M, Kirschner P, Meier A, Wrede A. Böttger EC. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA Pseudoknot. Mol Microbiol 1993;9:1239-1246.
75. Honoré N, Marchal G, Cole ST. Novel mutation in the 16S rRNA associated with streptomycin dependence in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:769-770.
76. Powers T, Noller HF. A functional pseudoknot in 16S ribosomal RNA. EMBO J 1991;10:2203-2214.
77. Benveniste R, Davies J. Mechanisms of antibiotic resistance in bacteria. Annu Rev Biochem 1973;42:471-506.
78. Crawford JT, Bates JH. Isolation of plasmids from mycobacteria. Infect Immunol 1979;24:979-981.
79. Martin C, Ranes M, Gicquel B. Plasmids, Antibiotic resistance, and mobile genetic elements in mycobacteria. In: McFadden J (ed) The Molecular Biology of the Mycobacteria. Surrey University Press, London. 1990:120-138.
80. Beggs WH, Andrews FA. Inhibition of dihydrostreptomycin binding to Mycobacterium smegmatis by monovalent and divalent cation salts. Antimicrob Agents Chemother 1976;9:393-396.
81. Bryan LE, van den Elzen HM. Effects of Membrane-energy mutations and cations on streptomycin and gentamicin accumulation by bacteria: a model for entry of streptomycin and gentamicin in susceptible and resistant bacteria. Antimicrob Agents Chemother 1977;12:163-177.
82. Trias J, Benz R. Characterization of the channel formed by the mycobacterial porin in lipid bilayer membranes. J Biol Chem 1993;268:6234-6240.
83. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem 1995;64:29-63.
84. Yeager RL, Munroe WGC, Dessau FI. Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952;65:523-534.
85. Tarshis MS, Weed Jr. WA. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc 1953;67:391-395.
86. McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 1954;70:748-754.
87. Mackaness GB. The intracellular activation of pyrazinamide and nicotinamide. Am Rev Tuberc Pulm Dis 1956;74:718-728.
88. Schwartz WS, Moyer RE. The Chemotherapy of pulmonary tuberculosis with pyrazinamide used alone and in combination with streptomycin, Para-aminosalicylic acid, or isoniazid. Am Rev Tuberc 1954;70:413-422.
89. Steenken Jr. W, Wolinsky E, Smith MM, Montalbine V. Further observations on pyrazinamide alone and in combination with other drugs in experimental tuberculosis. Am Rev Tuberc Pulm Dis 1957;76:643-659.
90. Crowle AJ, Dahl R, Ross E, May MH. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect Immunol 1991;59:1823-1831.
91. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, et al. Lack of acidification in mycobacterium phagosomes produced by exclusion of the vesicular proton ATPase. Science 1994;263:678-681.
92. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase, nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature Med 1996;2:662-7.
93. Konno K, Feldmann FM, McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 1967;95:461-469.
94. Forbes M, Kuck NA, Peets EA. Effect of ethambutol on nucleic acid metabolism in Mycobacterium smegmatis and its reversal by polyamines and divalent cations. J Bacteriol 1965;89:1299-1305.
95. Kilburn JO, Greenberg J. Effect of ethambutol on the viable cell count in Mycobacterium smegmatis. Antimicrob Agents Chemother 1977;11:534-540.
96. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989;33:1493-1499.
97. Sareen M, Khuller GK. Cell Wall and membrane changes associated with ethambutol resistance in Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1990;34:1773-1776.
98. Deng L, Mikusova K, Robuck KG, Scherman M, Brennan PJ, McNeil MR. Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Antimicrob Agents Chemother 1995;39:694-701.
99. Mikusova K, Slayden RA, Besra GS, Brennan PJ. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother 1995;39:2484-2489.
100. Belanger AE, Besra GS, Ford ME, Mikusovak, Belisle JT, Brennan PJ, Inanuke JM. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug elhambutal. Proc Natl Acad Sci USA 1996;93:11919-11924.
101. Garcia-Rodriguez JA, Gomez Garcia AC. In-vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993;32:797-808.
102. Renau TE, Sanchcz JP, Gage JW, Dever JA, Shapiro MA, Gracheck SJ, et al. Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7. J Med Chem 1996;39:729-35.
103. Fenlon CH, Cynamon MH. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob Agents Chemother 1986;29:386-388.
104. Leysen DC, Haemers A, Pattyn SA. Mycobacteria and the new quinolones. Antimicrob Agents Chemother 1989;33:1-5.
105. Witzig RS, Franzblau SG. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Antimicrob Agents Chemother 1993;37:1997-1999.
106. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993;37:407-413.
107. Hooper DC, Wolfson JS. Mechanisms of quinolone action and bacterial killing. In: Hooper DC and Wolfson JS (eds) Quinolone Antimicrobial Agents. American Society for Microbiology, Washington, D.C., 1993:53-76.
108. Oram M, Fisher LM. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified using the polymerase chain reaction. Antimicrob Agents Chemother 1991;35:387-389.
109. Goswitz JJ, Willard KE, Fasching CE, Peterson LR. Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin resistant Staphylococcus aureus: analysis by polymerase chain reaction and direct DNA sequencing. Antimicrob Agents Chemother 1992;36:1166-1169.
110. Wolfson JS, Hooper DC. Bacterial resistance to quinolones. Rev Infect Dis 1989;11:S960-S968.
111. Yoshida H, Bogaki M, Nakamura M, Yamanaka M, Nakamura S. Quinolone resistance-determining region in the DNA Gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 1991;35:1647-1650.
112. Takiff HE, Salazar L, Guerrero C, Huang WM, Kreisworth B, Cole S et al. Cloning and nucleotide sequence of the Mycobacterium tuberculosis gyrA and gyrB genes, and characterization of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773-780.
113. Cambau E, Sougakoff W, Besson M, Truffot PC, Grosset J, Jarlier V. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin (published erratum appears in J Infect Dis 1994;170:1351). J Infect Dis 1994;170:479-83.
114. Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimzadeh A, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995;345:1148-50.
115. Corti S, Chevalier J, Cremieux A. Intracellular accumulation of norfloxacin in Mycobacterium smegmatis. Antimicrob Agents Chemother 1995;39:2466-2471.
116. Liu J, Takiff HE, Nikaido H. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by lfrA, a multidrug efflux pump. J Bacteriol 1996;178:3791-3795.
117. Takiff HE, Cimino M, Musso MC, Weisbrod T, Martinez R, Delgado MB, et al. Efflux pumps of the proton antiporter family confers low level fluoroquinolone resistance in M. smegmatis. Proc Natl Acad Sci USA 1996;93:362-366.
118. Nikaido H. Prevention of drug access to bacterial targets: Permeability barriers and active efflux. Science 1994;264:382-388.
119. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother 1992;36:695-703.
120. Heym B, Honoré N, Truffot-Pernot C, Banerjee A, Schurra C, Jacobs Jr. WR, et al. Implications of Multidrug-Resistance for the Future of Short-Course Chemotherapy of Tuberculosis: A Molecular Study. Lancet 1994;344:293-298.
121. Morris S, Bai G, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 1995;171:954-60.
122. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-532.
123. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-791.